The School of Foreign Languages, Jiujiang University, Jiujiang, China.
Medical School, Jiujiang University, Jiujiang, China.
Sci Rep. 2023 Mar 28;13(1):5069. doi: 10.1038/s41598-023-31226-2.
Numerous studies have indicated that STAT3 plays a key role in promoting oncogenesis and it is considered a potential therapeutic target for cancer treatment; however, there are no reports on STAT3 using pan-cancer analysis. Therefore, it is important to investigate the role of STAT3 in different types of tumors using pan-cancer analysis. In the present study, we used multiple databases to comprehensively analyze the relationship between STAT3 expression and prognosis, different stages of patients with cancer, investigate the clinical value of STAT3 in predicting prognosis, and the relationship between STAT3 genetic alteration and prognosis, drug sensitivity, and STAT3 expression, to determine whether STAT3 participates in tumor immunity, to provide a rationale for STAT3 as a treatment target for a broad-spectrum malignancies. Our results indicate that STAT3 can serve as a prognostic, sensitivity prediction biomarker and a target for immunotherapy, which has been of great value for pan-cancer treatment. Overall, we found that STAT3 significantly predicted cancer prognosis, drug resistance, and immunotherapy, providing a rationale for further experimental studies.
大量研究表明 STAT3 在促进肿瘤发生中起着关键作用，被认为是癌症治疗的潜在治疗靶点；然而，目前尚无关于 STAT3 通过泛癌症分析的报道。因此，使用泛癌症分析研究 STAT3 在不同类型肿瘤中的作用非常重要。在本研究中，我们使用多个数据库全面分析了 STAT3 表达与预后、癌症患者不同分期之间的关系，探讨了 STAT3 预测预后的临床价值，以及 STAT3 遗传改变与预后、药物敏感性和 STAT3 表达之间的关系，以确定 STAT3 是否参与肿瘤免疫，为 STAT3 作为广谱恶性肿瘤治疗靶点提供理论依据。我们的研究结果表明，STAT3 可作为预后、敏感性预测生物标志物和免疫治疗靶点，对泛癌症治疗具有重要价值。综上所述，我们发现 STAT3 显著预测癌症预后、耐药性和免疫治疗，为进一步的实验研究提供了理论依据。
